Overview

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
BioNumerik Pharmaceuticals, Inc.
Collaborator:
Crown Bioscience
Treatments:
Camptothecin